Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome

    Research output: Contribution to journalLetterResearchpeer-review

  3. High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A user's guide to multicolor flow cytometry panels for comprehensive immune profiling

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lasse Hjort Jakobsen
  • Andreas Kiesbye Øvlisen
  • Marianne Tang Severinsen
  • Joachim Bæch
  • Kristian Hay Kragholm
  • Ingrid Glimelius
  • Anne Ortved Gang
  • Judit Mészáros Jørgensen
  • Henrik Frederiksen
  • Christian Bjørn Poulsen
  • Michael Roost Clausen
  • Per Trøllund Pedersen
  • Robert Schou Pedersen
  • Christian Torp-Pedersen
  • Sandra Eloranta
  • Tarec Christoffer El-Galaly
View graph of relations

For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60-70% of patients remain progression-free after 5 years. Given a median age of 65, it is relevant to disentangle how DLBCL and DLBCL therapy influence health care use among the survivors. In this nationwide study, the health care use among Danish DLBCL patients diagnosed in 2007-2015, who achieved complete remission after R-CHOP(-like) therapy, was explored and compared to matched comparators from the Danish general population. The post-remission 5-year risk of hospitalization was significantly higher among DLBCL survivors (55%) compared to matched comparators (49%, P < 0.001). DLBCL survivors had on average 10.3 (9.3-11.3) inpatient bed days within 5 years of response evaluation, whereas matched comparators had 8.4 (7.9-8.8). The rate of outpatient visits was also significantly higher(excluding routine follow-up visits, incidence rate ratio, 1.3, P < 0.001), but translated into only a very small absolute difference of <1 outpatient visits within 5 years between DLBCL survivors (4.2 visits, 95% CI, 4.0-4.4) and matched comparators (3.8 visits, 95% CI, 3.7-3.9). In conclusion, DLBCL survivors have an increased incidence of hospital visits due to a wide range of conditions, but in absolute terms the excess use of health care services in DLBCL survivors was small.

Original languageEnglish
Article number16
JournalBlood Cancer Journal
Volume12
Issue number1
Pages (from-to)16
ISSN2044-5385
DOIs
Publication statusPublished - 27 Jan 2022

Bibliographical note

© 2022. The Author(s).

ID: 73254935